Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy ...
From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and a $322 million ...
Daniel Dornbusch (ddornbusch@mba2003.hbs.edu) leads the medical education team in Genentech?s Hematology Division. He previously worked for Genzyme, specializing in business, product, and corporate ...
Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not ...
Amplitude Therapeutics and Chai Discovery ink AI and RNA collaborations with Eli Lilly and Bristol Myers Squibb, Norstella's ...
K2 Therapeutics CEO Ying Huang discusses why government investment and US-trained returnees have made China's biotech ...
A changing of the guard atop Pharm Exec’s latest listing of the top biopharma Rx revenue producers reflects an industry being remade in real time, becoming as much a map of franchise quality and ...
Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated approval for multiple myeloma, and PwC's Glenn Hunzinger talks the shifting ...
However, in a conversation with Norstella’s VP of thought leadership Dan Chancellor, he explained that pipeline creation has ...
President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for ...
Chai Discovery has announced a collaboration with Bristol Myers Squibb to advance the discovery of therapeutic antibodies using artificial intelligence.
FDA approval in adult FOP targets disease-driving Activin A biology, addressing progressive heterotopic ossification that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results